Current
26.4×
5-Year Average
25.9×
All-Time High
233.6×
All-Time Low
17.8×
P/E Ratio daily chart for Vertex Pharmaceuticals (VRTX)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
P/E ratio is not shown for periods when TTM earnings were negative.
Historical P/E Ratio for Vertex Pharmaceuticals (VRTX) from 2001 to 2025
| 2025 | $115.11B | $3.95B | 29.1× | — | |
| 2024 | $103.70B | −$535.60M | — | — | |
| 2023 | $104.86B | $3.62B | 29.0× | +6.6× | |
| 2022 | $74.19B | $3.32B | 22.3× | -1.5× | |
| 2021 | $55.91B | $2.34B | 23.9× | +1.2× | |
| 2020 | $61.46B | $2.71B | 22.7× | -25.3× | |
| 2019 | $56.49B | $1.18B | 48.0× | +27.9× | |
| 2018 | $42.23B | $2.10B | 20.1× | -122.9× | |
| 2017 | $37.70B | $263.48M | 143.1× | — | |
| 2016 | $18.08B | −$115.05M | — | — | |
| 2015 | $30.13B | −$558.12M | — | — | |
| 2014 | $28.26B | −$738.55M | — | — | |
| 2013 | $17.18B | −$445.02M | — | — | |
| 2012 | $8.99B | −$107.03M | — | — | |
| 2011 | $6.91B | $29.57M | 233.6× | — | |
| 2010 | $7.05B | −$754.63M | — | — | |
| 2009 | $8.52B | −$642.18M | — | — | |
| 2008 | $4.52B | −$459.85M | — | — | |
| 2007 | $3.04B | −$391.28M | — | — | |
| 2006 | $4.64B | −$206.89M | — | — | |
| 2005 | $2.97B | −$203.42M | — | — | |
| 2004 | $835.82M | −$166.25M | — | — | |
| 2003 | $804.88M | −$152.64M | — | — | |
| 2002 | $1.21B | −$108.62M | — | — | |
| 2001 | $1.84B | −$71.22M | — | — |
- 202529.1×
- 2024—
- 202329.0×
- 202222.3×
- 202123.9×
- 202022.7×
- 201948.0×
- 201820.1×
- 2017143.1×
- 2016—
- 2015—
- 2014—
- 2013—
- 2012—
- 2011233.6×
- 2010—
- 2009—
- 2008—
- 2007—
- 2006—
- 2005—
- 2004—
- 2003—
- 2002—
- 2001—
About P/E Ratio at Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) P/E ratio is 26.4× as of June 5, 2026. The 5-year average is 25.9×. The sector median currently stands at 25.0×. The current ratio is at the 38th percentile of its own 10-year history.
Vertex Pharmaceuticals (VRTX) historical P/E ratio has ranged from a low of 17.8× (2021) to a high of 233.6× (2011) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Vertex Pharmaceuticals P/E Ratio by Year
Vertex Pharmaceuticals P/E Ratio 2025: 29.1×
Vertex Pharmaceuticals (VRTX) P/E ratio in 2025 was 29.1×, expanded from 29.0× the prior year.
Vertex Pharmaceuticals P/E Ratio 2023: 29.0×
Vertex Pharmaceuticals (VRTX) P/E ratio in 2023 was 29.0×, expanded from 22.3× the prior year.
Vertex Pharmaceuticals P/E Ratio 2022: 22.3×
Vertex Pharmaceuticals (VRTX) P/E ratio in 2022 was 22.3×, contracted from 23.9× the prior year.
Vertex Pharmaceuticals P/E Ratio 2021: 23.9×
Vertex Pharmaceuticals (VRTX) P/E ratio in 2021 was 23.9×, expanded from 22.7× the prior year.
Vertex Pharmaceuticals P/E Ratio 2020: 22.7×
Vertex Pharmaceuticals (VRTX) P/E ratio in 2020 was 22.7×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by P/E ratio.
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric